Form 8-K - Current report:
SEC Accession No. 0001087294-25-000023
Filing Date
2025-11-24
Accepted
2025-11-21 20:26:32
Documents
13
Period of Report
2025-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20251118.htm   iXBRL 8-K 28810
2 EX-10.1 cumberlandpharm-1stamdtoar.htm EX-10.1 30745
  Complete submission text file 0001087294-25-000023.txt   181505

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20251118.xsd EX-101.SCH 1894
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20251118_lab.xml EX-101.LAB 21900
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20251118_pre.xml EX-101.PRE 12611
15 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20251118_htm.xml XML 2828
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 251509400
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)